Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder | Danskeaktier.com

Fondsbørsmeddelelse

Læs den fulde meddelelse hos Globenewswire:
Gå til Globenewswire

Valby, Denmark, and Osaka, Japan, 8 June 2018 - H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today announced positive results from the pivotal study with vortioxetine in adults with Major Depressive Disorder conducted in Japan. Both companies intend to move forward with regulatory filing of vortioxetine later this year to the Ministry of Health, Labor and Welfare in Japan.   

Vi indsamler aktuelle aktiekurser og fondsbørsmeddelelser for alle danske aktier.
Se også vores aktietips og aktieanbefalinger eller deltag i vores aktiekursus

Mest populære aktie: Novo Nordisk Aktie